Cipher Pharmaceuticals appoints Rajiv De Silva to board of directors

By Public Technologies
  • Cipher Pharmaceuticals appointed Rajiv De Silva to its board, effective today.
  • De Silva brings more than 30 years in healthcare, including board roles, executive leadership, high-growth strategy, mergers, acquisitions.
  • Most recently CEO of Venus Concept; previously chair at Covis Pharma, CEO and director of Endo International.
  • Earlier roles included executive positions at Valeant Pharmaceuticals and Novartis; formerly a management consultant at McKinsey.
  • Board expands to four members, with three independent directors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cipher Pharmaceuticals Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609211700CANADANWCANADAPR_C5041) on September 21, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk